Regeneron Reports Second Quarter 2021 Financial and Operating Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. ANT
4. SPY
5. CART
6. TSLA
7. FFR
8. XNCR
9. AZN
10. GMAB

Go back to Regeneron Reports Second Quarter 2021 Financial and Operating Results

Regeneron (REGN) Tops Q2 EPS by $8.11, Sales Pounce Consensus

August 5, 2021 6:33 AM EDT

Regeneron (NASDAQ: REGN) reported Q2 EPS of $25.80, $8.11 better than the analyst estimate of $17.69. Revenue for the quarter came in at $5.14 billion versus the consensus estimate of $3.89 billion.

Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COVTM(2); revenues excluding REGEN-COV(1)(2) increased 22%Second quarter 2021 EYLEA® U.S. net sales increased 28% versus second quarter 2020 to a record $1.42 billionSecond quarter 2021 Dupixent® global net sales(3), which are recorded by Sanofi, increased 59% to... More